Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Our mission is to discover new ways to improve and extend people’s lives. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. That is our purpose.
Our global portfolio comprises approximately 1 000 molecules, covering all major therapeutic areas, which accounted for 2015 sales of USD 10.1 billion. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
Our products reach more than 500 million patients and our aspiration is to reach one billion. Our broad portfolio is spearheaded by our global leadership position in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the foundation of global healthcare systems. We also run a broad range of targeted corporate responsibility programs to increase access to medicine, medical information and appropriate medical training for healthcare professionals.
Sandoz is headquartered in Holzkirchen, in Germany’s greater Munich area.
Contact
Address: Pilgrim Bldg, 111 Aguirre, Legazpi Village, Makati, 1229 Kalakhang Maynila
Phone: (02) 815 0505
Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the booming generic industry over the past years has helped…
Mr. Willis, you have a background as a management consultant in New Zealand and Australia. What was the situation of the generics market when you arrived in the Philippines and…
Keren Haruvi, President of Sandoz North America, reflects on the company’s transformation following its spin-off from Novartis and outlines how Sandoz is positioning itself at the forefront of the evolving…
Will Hsu leads Sandoz operations across Taiwan, Hong Kong, and Macao, managing a portfolio spanning both generics and biosimilars in markets characterised by universal healthcare and significant budget constraints. With…
Alexander Salzmann with nearly a decade at Sandoz, reflects on the company’s transition from a Novartis division to an independent, Swiss-listed entity. In this interview, Salzmann discusses the challenges and…
As healthcare systems grapple with rising costs and the need for broader access to treatment, off-patent medicines have taken on increasing importance. With budgets under pressure and blockbuster drugs losing…
A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
After a turbulent five-year tenure, Kare Schultz will be stepping down as the Israeli generics giant ‘s CEO and former Sandoz chief Richard Francis will take over in January. Francis,…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR…
After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its core business and which is part…
The outbreak of the COVID-19 pandemic put an end to more than five years of economic growth in Spain. But the country was not alone. Due to strict containment measures,…
The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his…
See our Cookie Privacy Policy Here
